# 1 N/A

**Page range:** 19â€“20

```text
1. N/A
2. Open label
3. Parallel
4. Non-Controlled
JO43175
A Phase I Study of Pralsetinib in Patients
With RET Altered Solid Tumor
Phase I
1. Nonrandomized
2. Open label
3. Single Group
4. Non-Controlled

20
Drug Safety Report No: 1132062
Study
Number
Study Title
Study
Phase
Study Design
[Randomisation,
Blinding, Design,
Comparison]
JO43701
A Phase II Study of Pralsetinib in Patients
with Previously Treated RET Fusion
Positive Non-Small Cell Lung Cancer
Phase II
1. Nonrandomized
2. Open label
3. Single Group
4. Non-Controlled
ML41591
Nautika1: A Multicenter, Phase II,
Neoadjuvant and Adjuvant Study of Multiple
Therapies in Biomarker-Selected Patients
with Resectable Stages Ib-III Non-Small
Cell Lung Cancer
Phase II
1. Nonrandomized
2. Open label
3. Single Group
4. Non-Controlled
ML42439
Mytactic: An Open-Label Phase II Study
Evaluating Targeted Therapies in Patients
who have Advanced Solid Tumors With
Genomic Alterations Or Protein Expression
Patterns Predictive Of Response
Phase II
1. Nonrandomized
2. Open label
3. Parallel
4. Non-Controlled
CYP: Cytochrome P450
Of the studies reported in Table 1, BO42864 (AcceleRET-Lung) and BO42863
(ARROW) are included for trial case analysis. Safety data from the AcceleRET-Lung
study triggered this analysis. Additionally, the ARROW study is being included as it
provides a larger dataset of patients and the current labelling documents for Gavreto are
based on the results of this study.
```